Antibody-dependent enhancement in dengue virus infections [2]

Journal of Infectious Diseases

Volumn 193, Issue 4, 2006, Pages 601-603

  Burke, Donald S ^a   Kliks, Srisakul ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Pediatric Dengue Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; GEOGRAPHIC ORIGIN; HUMAN; HUMAN TISSUE; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEROTYPE; VIREMIA; VIRUS NEUTRALIZATION; VIRUS PLAQUE;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; DENGUE VIRUS;

EID: 32044446023     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/499282     Document Type: Letter

References (10)

1. Laoprasopwattana K, Libraty DH, Endy TP, et al. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005; 192: 510-9.
2. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
3. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411-9.
4. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239: 476-81.
5. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
6. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120:653-69.
7. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000.
8. Kochel TJ, Watts DM, Halstead SB, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002; 360:310-2.
9. Klein E, Ben-Bassat H, Neumann H, et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976; 18:421-31.
10. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90.